Key result
Antigenic maps of AAVs visualize relationships to address challenges in evaluating humoral responses.
Why the study?
The host immune response poses a significant challenge to the clinical success of adeno-associated virus gene therapy vectors, particularly in evaluating the humoral response.
This review highlights challenges in evaluating humoral immune responses to AAV gene therapy vectors and presents the first antigenic maps of AAV serotypes.
Antigenic maps may guide AAV vector selection in gene therapy; leaves open prospective validation of humoral response predictions.
Adeno-associated viruses (AAVs) are non-pathogenic, replication-deficient viruses that have gained widespread attention for their application as gene therapy vectors. While these vectors offer high transduction efficiency and long-term gene expression, the host immune response poses a significant challenge to their clinical success. This review focuses on the obstacles to evaluating the humoral response to AAVs. We discuss the problems with the validation of in vitro tests and the possible approaches to overcome them. Using published data on neutralizing titers of AAV serotypes, we built the first antigenic maps of AAVs in order to visualize the antigenic relationships between varying serotypes.
No takes yet. Share an insight, caveat, or question.
Naumova et al. (2025) conducted a review in Humoral immune response to Adeno-Associated Viruses. Adeno-Associated Viruses (AAVs) was evaluated. Antigenic maps of adeno-associated viruses (AAVs) were constructed using published neutralizing titer data to visualize antigenic relationships and address challenges in evaluating humoral responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: